The present invention provides compounds having formula (I): (I) wherein n, R
1
-R
5
, R
a
-R
b
, Q, Y
1
and Y
2
are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis.
GLUTARIMIDE-CONTAINING POLYKETIDE ANALOGS AND METHODS THEREOF
申请人:Shen Ben
公开号:US20060211736A1
公开(公告)日:2006-09-21
The present invention provides library of glutarimide-containing polyketide analogs, such as analogs of migrastatin, iso-migrastatin, dorrigocin A and B, epi-dorrigocin, NK30424 A and B and lactimidomycin, methods of synthesizing and using these analogs and further methods of creating a combinatorial library of these compounds through chemical modifications.
Iso-Migrastatin Congeners from <i>Streptomyces </i><i>p</i><i>latensis</i> and Generation of a Glutarimide Polyketide Library Featuring the Dorrigocin, Lactimidomycin, Migrastatin, and NK30424 Scaffolds
Iso-Migrastatin (10) has been shown to be the main natural product of Streptomyces platensis, which undergoes a facile, H2O-mediated rearrangement into dorrigocin A (2), 13-epi-dorrigocin A (11), dorrigocin B (3), and migrastatin (1). Eight new congeners (12-19) of 10 were characterized. They can undergo the same H2O-mediated rearrangement into the corresponding 1, 2, 3, and 11 analogues (20-43) or 1,4-Michael addition with cysteine to afford the corresponding analogues (44-51) of NK30424 A and B (5, 6). This study generated a 47-member library of glutarimide polyketides, setting the stage to investigate the SAR for this family of natural products. These results also established the absolute stereochemistry of 5 and 6 and shed new light into the post-polyketide synthase steps for 10 biosynthesis.
FASCIN BINDING COMPOUNDS FOR SPINOGENESIS
申请人:SPINOGENIX, INC.
公开号:US20210330646A1
公开(公告)日:2021-10-28
In some embodiments, a method of promoting spinogenesis in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2 or binding site 3.